PD-15 Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments

Mara Persano; M. Rimini; T. Toshifumi; Goki Suda; S. Shigeo; Masatoshi Kudo; Jaekyung Cheon; F. Finkelmeier; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Francesco Tovoli; F. Piscaglia; Massimo Iavarone; Fabio Marra; E. Tamburini; Giuseppe Cabibbo; M. Scartozzi; Andrea Casadei‐Gardini

doi:10.1016/j.annonc.2023.04.042

Related publications

Article2023

Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments

Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Fabio Piscaglia, Massimo Iavarone, Giuseppe Costanzo, Fabio Marra, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Siletta, Stefano Cascinu, Mario Scartozzi, Andrea Casadei‐Gardini

Article2023

Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Takashi Niizeki, Margarida Montes, Caterina Vivaldi,

Article2023

972P Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma

Mara Persano, M. Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, F. Piscaglia, Massimo Iavarone, Emiliano Tamburini, Giuseppe Cabibbo, Marianna Silletta, Stefano Cascinu, Mario Scartozzi, A. Casadei Gardini

Article2023

165P BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab

Elisabeth Amadeo, M. Persano, Toshifumi Tada, Goki Suda, S. Shimose, Masatoshi Kudo, Changhoon Yoo, Federico Rossari, Francesco Vitiello, A. Casadei Gardini, M. Rimini

Article2024

Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab

Margherita Rimini, Bernardo Stefanini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Fabian Finkelmeier, Changhoon Yoo, José Presa, Elisabeth Amadeo, V. Genovesi, Maria Caterina De Grandis, Massimo Iavarone, Fabio Marra, Francesco Giuseppe Foschi, Emiliano Tamburini, Federico Rossari, Francesco Vitiello, L. Bartalini, Caterina Soldà, Francesco Tovoli, Caterina Vivaldi,

PD-15 Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments

Discussion(0)

Related publications

Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments

Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

972P Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma

165P BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab

Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab